Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. (NYSE: RMD) drives innovation in digital health and respiratory care through cloud-connected medical devices and remote patient management platforms. This news hub provides investors and healthcare professionals with timely updates on the company's market activities and clinical advancements.
Access curated press releases, earnings reports, and regulatory filings alongside analysis of product launches and partnership announcements. Our repository tracks developments across ResMed's core focus areas: sleep apnea solutions, COPD management technologies, and out-of-hospital care software platforms.
Stay informed about FDA clearances, clinical trial results, and global market expansions through verified sources. The page serves as a comprehensive resource for monitoring ResMed's progress in merging medical device engineering with data-driven healthcare solutions.
Bookmark this page for streamlined access to strategic updates impacting respiratory care innovation and digital health investment opportunities. Check regularly for new developments in ResMed's mission to transform chronic disease management worldwide.
ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:20 p.m. EDT. The chat will be available via a live video webcast, with a replay accessible approximately 12 hours after the event, remaining available until June 8, 2022. ResMed focuses on innovative health solutions for chronic diseases, aiming to improve quality of life and lower healthcare costs globally.
ResMed (NYSE: RMD) announced that Rob Douglas, president and COO, will participate in a virtual fireside chat at the William Blair 41st Annual Growth Stock Conference on June 1, 2021, at 1:20 p.m. CDT. The event will be accessible via video webcast, with a replay available approximately 24 hours after the event and lasting until July 1, 2021. ResMed focuses on innovative solutions for chronic diseases, helping improve patient quality of life and reduce healthcare costs worldwide.
ResMed (NYSE: RMD) reported its third-quarter fiscal 2021 results, revealing a 3% year-over-year increase in net operating profit but a non-GAAP revenue drop to $768.8 million, down 3% on a constant currency basis. The GAAP diluted EPS was $(0.54), compared to $1.12 last year, primarily due to a $255 million reserve related to tax disputes. Non-GAAP diluted EPS rose by 1% to $1.30. Additionally, operational cash flow was $196.3 million, and a quarterly cash dividend of $0.39 per share was declared.
ResMed (NYSE: RMD) announced that CFO Brett Sandercock will present virtually at the Macquarie Australia Conference on May 5, 2021, at 8:45 a.m. AEST. This event will be accessible via video webcast, with a replay available for Macquarie clients 24 hours post-event until May 26, 2021. ResMed is known for its innovative digital health technologies and cloud-connected devices aimed at improving care for chronic diseases like sleep apnea and COPD, effectively transforming healthcare delivery worldwide.
ResMed plans to release its third-quarter fiscal year 2021 financial results on April 29, 2021, post-market closure. The earnings call will be hosted by management at 1:30 p.m. PDT (4:30 p.m. EDT) with an international audience included. A webcast link for the earnings results is provided for stakeholders. A replay of the webcast will be available shortly after, with a phone replay accessible until May 13, 2021. ResMed is committed to providing innovative healthcare solutions for chronic diseases worldwide, with operations in over 140 countries.
ResMed (NYSE: RMD) has announced that Rob Douglas, president and COO, and Brett Sandercock, CFO, will participate in a virtual fireside chat at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 23, 2021, at 4:15 p.m. EDT. The event will be accessible via a video webcast. A replay will be available one hour post-event until June 21, 2021. ResMed focuses on innovative solutions to treat chronic diseases, providing digital health technologies and cloud-connected medical devices that enhance the quality of life for patients globally.
MatrixCare announced that its Home Health and Hospice EHR solution has been awarded Best in KLAS for Home Health EHR (Large) for the second consecutive year. The solution achieved a Home Health score of 88.3, up from 87.1 last year, leading competitors by 2 points. In the Hospice category, MatrixCare leads by 13.2 points, to be recognized in next year's awards. The company focuses on innovation and customer support, especially during the pandemic, and will be acknowledged in a virtual awards ceremony on February 23.
ResMed reported a strong performance for the second quarter of 2021, with a 9% increase in revenue to $800.0 million. Net operating profit rose 12%, and GAAP diluted EPS grew to $1.23. These results were supported by growth in core markets like sleep apnea and COPD despite a 20 basis point contraction in gross margin due to restructuring expenses. Notably, non-GAAP EPS improved by 17%. The company also declared a quarterly cash dividend of $0.39 per share, demonstrating financial strength as it aims to enhance digital health solutions.
ResMed (NYSE: RMD, ASX: RMD) will release its financial and operational results for Q2 of fiscal 2021 on January 28, 2021, post-market close. A webcast is scheduled to follow, where management will discuss results and potentially other forward-looking information.
The earnings webcast will take place at 1:30 p.m. PST / 4:30 p.m. EST, with international times provided for London and Sydney. A replay will be available on ResMed’s website within two hours of the event and will also feature a phone replay option available until February 11.
